Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-arm, Open-label, Expanded Access Program to Provide 100 mg CT1812 (Zervimesine) and to Collect Long-term Safety and Efficacy Data in Participants With Mild-to-moderate Dementia With Lewy Bodies (DLB).

Next Previous
Trial Profile

A Single-arm, Open-label, Expanded Access Program to Provide 100 mg CT1812 (Zervimesine) and to Collect Long-term Safety and Efficacy Data in Participants With Mild-to-moderate Dementia With Lewy Bodies (DLB).

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 17 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zervimesine (Primary)
  • Indications Dementia; Lewy body disease
  • Focus Expanded access; Therapeutic Use
  • Sponsors Cognition Therapeutics

Most Recent Events

  • 05 Feb 2026 According to a Cognition Therapeutics media release, thirty-two individuals were enrolled at eight sites in this open-label EAP, each of whom are being treated with 100 mg of oral zervimesine daily. Banner Sun Health Research Institute in Arizona was the first site to be activated and enrolled the first participants. David Shprecher, DO Msci is the primary investigator at Banner and provided feedback to the Cognition team during the design of the EAP.
  • 05 Feb 2026 According to a Cognition Therapeutics media release, the company has extended the duration of the expanded access program (EAP) for dementia with Lewy bodies (DLB). The program, which was originally expected to provide each participant with twelve months of treatment, will now allow several more months of treatment.
  • 03 Dec 2025 According to a Cognition Therapeutics media release, company announced that its expanded access program has reached full enrollment

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top